The investigating of the effect of curcumin and zinc co-supplementation on glycemic measurements, lipid profiles, inflammatory and antioxidant biomarkers in pre-diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190902044671N1

Enrollment

Registered

2019-10-11

Start date

2019-11-11

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-diabetic. Abnormal glucose tolerance test

Interventions

Intervention 1: Intervention group: curcumin supplement. Intervention 2: Intervention group: zinc supplement. Intervention 3: Intervention group: curcumin supplement+zinc supplement. Intervention 4: C

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: both genders age: 18-50 years (for women 18 years before menopause individuals with IFG =100-125 (mg/dL), IGT =140-199(mg/dL), or/and HbA1c=% 6.4 -5.7 , individuals with BMI=25-35 No use of blood glucose-lowering drugs such as Metformin or Glucophage individuals with written informed consent from patients

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Serum insulin. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Hemoglobin A1c. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Serum triglyceride. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Insulin resistance. Timepoint: at the beginning and end of study. Method of measurement: insulin resistance formula (HOMA-IR).;Insulin sensitivity. Timepoint: at the beginning and end of study. Method of measurement: insulin sensitivity formula.;Beta-cell function. Timepoint: at the beginning and end of study. Method of measurement: formula.;Total cholesterol. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Serum Low Density lipoprotein -Cholesterol (LDL-C). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Serum Low Density lipoprotein -Cholesterol (HDL-C ). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Malondialdehyde (MDA). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Total Antioxidant Capacity (TAC). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Serum zinc. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Interleukin 1-B (IL-1B ). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;C- Reaction Protein (CRP). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;High sensitivity C- Reaction Protein(hs-CRP). Timepoint: at the beginning and end of study. Method of measurement: serum sample.	—

Measure

Time frame

Fasting blood glucose. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Serum insulin. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Hemoglobin A1c. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Serum triglyceride. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Insulin resistance. Timepoint: at the beginning and end of study. Method of measurement: insulin resistance formula (HOMA-IR).;Insulin sensitivity. Timepoint: at the beginning and end of study. Method of measurement: insulin sensitivity formula.;Beta-cell function. Timepoint: at the beginning and end of study. Method of measurement: formula.;Total cholesterol. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Serum Low Density lipoprotein -Cholesterol (LDL-C). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Serum Low Density lipoprotein -Cholesterol (HDL-C ). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Malondialdehyde (MDA). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Total Antioxidant Capacity (TAC). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Serum zinc. Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Interleukin 1-B (IL-1B ). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;C- Reaction Protein (CRP). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;High sensitivity C- Reaction Protein(hs-CRP). Timepoint: at the beginning and end of study. Method of measurement: serum sample.

—

Secondary

Measure	Time frame
Aspartate Transaminase (AST). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Alanine Transaminase (ALT). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Weight. Timepoint: at the beginning,and end of the study. Method of measurement: seca scales.;Height. Timepoint: at the beginning. Method of measurement: stadiometer.;Waist circumference. Timepoint: at the beginning,and end of the study. Method of measurement: tape.;Hip circumference. Timepoint: at the beginning,and end of the study. Method of measurement: tape.;Blood pressure. Timepoint: at the beginning,and end of the study. Method of measurement: Korotkoff sound technique with a calibrated mercury sphygmomanometer.;Body composition (fat mass (FM), free fat mass (FFM), muscle mass (MM)). Timepoint: at the beginning,and end of the study. Method of measurement: bioelectrical impedance analysis (BIA) method by a Body Composition Analyzer (InBody 270, Seoul, South Korea).;Dietary intake (energy, carbohydrate, fat, protein). Timepoint: at the beginning,and end of the study. Method of measurement: using Nutritionist IV software.;Physical activity. Timepoint: at the beginning,and end of the study. Method of measurement: Short form of the International Physical Activity Questionnaire (IPAQ-SF).;Health-related quality of life. Timepoint: at the beginning,and end of the study. Method of measurement: SF-36 questionnaire.	—

Measure

Time frame

Aspartate Transaminase (AST). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Alanine Transaminase (ALT). Timepoint: at the beginning and end of study. Method of measurement: serum sample.;Weight. Timepoint: at the beginning,and end of the study. Method of measurement: seca scales.;Height. Timepoint: at the beginning. Method of measurement: stadiometer.;Waist circumference. Timepoint: at the beginning,and end of the study. Method of measurement: tape.;Hip circumference. Timepoint: at the beginning,and end of the study. Method of measurement: tape.;Blood pressure. Timepoint: at the beginning,and end of the study. Method of measurement: Korotkoff sound technique with a calibrated mercury sphygmomanometer.;Body composition (fat mass (FM), free fat mass (FFM), muscle mass (MM)). Timepoint: at the beginning,and end of the study. Method of measurement: bioelectrical impedance analysis (BIA) method by a Body Composition Analyzer (InBody 270, Seoul, South Korea).;Dietary intake (energy, carbohydrate, fat, protein). Timepoint: at the beginning,and end of the study. Method of measurement: using Nutritionist IV software.;Physical activity. Timepoint: at the beginning,and end of the study. Method of measurement: Short form of the International Physical Activity Questionnaire (IPAQ-SF).;Health-related quality of life. Timepoint: at the beginning,and end of the study. Method of measurement: SF-36 questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Azhdari

Ahvaz University of Medical Sciences

azhdari_mar@yahoo.com+98 35 3821 9196

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 25, 2026